FDA Safety Concerns Force Fulcrum Therapeutics to Halt Sickle Cell Drug Development
核心洞察
Fulcrum Therapeutics discontinued development of pociredir for sickle cell disease (搜索) after FDA expressed heightened concerns about cancer risk associated with PRC2 complex (搜索) inhibitors.
The FDA's decision was triggered by the global withdrawal of Tazverik (tazemetostat) in March 2026 due to unexpectedly high rates of secondary hematologic malignancies (搜索).
With pociredir representing the company's only clinical-stage asset, Fulcrum has initiated a strategic review to explore merger, acquisition, or other transactions to maximize shareholder value.
Fulcrum Therapeutics announced the complete discontinuation of pociredir development for sickle cell disease (搜索) following FDA feedback that eliminated any viable regulatory pathway for the experimental treatment. The decision, disclosed Monday, sent shares of the clinical-stage biotech company down 49% in after-hours trading and leaves Fulcrum without any clinical-stage assets.
FDA Raises Class-Wide Safety Concerns
The FDA's position stems from heightened concerns about the benefit-risk profile of pociredir, an EED (搜索) inhibitor that targets the PRC2 complex (搜索). On May 28, Fulcrum received meeting minutes in which the agency expressed these concerns, triggered by the global withdrawal of Tazverik (tazemetostat), another PRC2 inhibitor, in March 2026 after it showed an unexpectedly high rate of secondary hematologic malignancies (搜索).
The FDA concluded that any pharmacological intervention targeting the PRC2 complex (搜索) carries equivalent malignancy risk. This stance, combined with previously disclosed preclinical malignancy observations for pociredir, left no viable regulatory path forward for the drug candidate.
"Following a thorough review of regulatory feedback, the totality of available data, and the implications for a viable regulatory path, we have made the very difficult decision to discontinue development of pociredir," said Alex C. Sapir, Fulcrum's president and chief executive officer. Sapir noted that no new safety signals have emerged in human trials of pociredir to date, but the FDA's position on class-wide risk outweighed the drug's observed clinical benefits.
Pipeline Depletion Forces Strategic Review
With the discontinuation of pociredir, Fulcrum has lost its only clinical-stage asset, leaving the company essentially with no near-term pipeline. Earlier programs, such as losmapimod for facioscapulohumeral muscular dystrophy (搜索), had already been discontinued after a failed 2024 trial. Pociredir had held Fast Track and Orphan Drug designations from the FDA for sickle cell disease (搜索), a genetic blood disorder.
In conjunction with the program termination, Fulcrum has initiated a comprehensive strategic review to explore alternatives aimed at maximizing stockholder value. These may include a merger, acquisition, business combination, or other transactions involving the company or its assets. The company is also taking steps to significantly reduce operating expenses and preserve capital.
The company has not set a timeline for concluding the review and does not plan further updates unless a transaction is approved or other disclosure becomes appropriate. The regulator's observations left no viable regulatory path forward for pociredir, forcing the company to explore strategic alternatives to preserve shareholder value.